Background: The incidence of hypertension and clinical complications
(e.g., heart, cerebrovascular and kidney injury) is increasing worldwide. It is
widely known that a relatively large dose of valsartan (320 mg) could alleviate
clinical complications. The current network meta-analysis assessed which drug
could be combined with a relatively large dose of valsartan to control blood
pressure (BP) more effectively. And which combination therapy with different
dosages of valsartan did not induce excessive BP reduction with increasing
dosages of valsartan. Methods: The PubMed, Embase, Medline, Cochrane
Library, CNKI, Wanfang, and CSTJ databases were searched from inception to
October 2022 for relevant randomized controlled trials (RCTs). The search
strategies included concepts related to hypertension and two-drug combination
therapy of different doses of valsartan, and there were no language or data
restrictions. The outcomes included adverse effects and changes in systolic BP
and diastolic BP. Permanent discontinuations related to treatment were the most
accurate and objective measure of adverse effects. The common adverse effects of
most studies (i.e., dizziness, headache, nasopharyngitis, asthenia and urticaria)
were also included. A Bayesian network meta-analysis was performed, and mean
differences with 95% confidence intervals were calculated. ADDIS and STATA were
used for Bayesian model network meta-calculation. Results: Thirty-four
RCTs were included involving 26,752 patients, and the interventions included
different doses of valsartan combined with various types and doses of drugs.
Among many combination therapies, the combination of valsartan 320 mg with
amlodipine 10 mg (p
Announcements
Open Access
Systematic Review
Two-Drug Combinations Therapy of Different Doses of Valsartan Existing Diverse Significance for Hypertensive Patients
Zerong Wang1, Shixiong Wang2, Liqiong Zhang1, Jiaxuan Wang1, Rong Wang1, Shude Chen1, Qiling Shi1, Hongye Wu1, Liuyang Wang1, Ningyin Li3,*
Show Less
1
The Second Clinical Medical College, Lanzhou University, 730000 Lanzhou, Gansu, China
2
Department of Cardiac Surgery, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China
3
Cardiovascular Department, Lanzhou University Second Hospital, 730030 Lanzhou, Gansu, China
*Correspondence: liny1517@163.com (Ningyin Li)
Rev. Cardiovasc. Med. 2023, 24(7), 187;
https://doi.org/10.31083/j.rcm2407187
Submitted: 23 November 2022 | Revised: 17 February 2023 | Accepted: 20 February 2023 | Published: 29 June 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract
Keywords
hypertension
blood pressure
valsartan
combined therapy
clinical complications
Funding
21JR1RA164/Youth Science and Technology Fund of Gansu Province
2020B-037/Innovation Fund for Higher Education of Gansu Province
CYXZ2021-41/Cuiying Scientific Training Program for Undergraduates of Lanzhou University Second Hosptial
Figures
Fig. 1.